| Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer X García-González, L Cortejoso, MI García, P García-Alfonso, L Robles, ... Oncotarget 6 (8), 6422, 2015 | 67 | 2015 |
| Identification of new SNPs associated with severe toxicity to capecitabine M Pellicer, X García-González, MI García, L Robles, C Grávalos, ... Pharmacological research 120, 133-137, 2017 | 52 | 2017 |
| Cost–effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines L Cortejoso, X García-González, MI García, P García-Alfonso, M Sanjurjo, ... Pharmacogenomics 17 (9), 979-984, 2016 | 43 | 2016 |
| Current use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution A Galar, P Muñoz, M Valerio, E Cercenado, X García-González, A Burillo, ... International journal of antimicrobial agents 53 (1), 40-48, 2019 | 39 | 2019 |
| Clinical implementation of pharmacogenetics X García-González, T Cabaleiro, MJ Herrero, H McLeod, ... Drug Metabolism and Personalized Therapy 31 (1), 9-16, 2016 | 35 | 2016 |
| Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis S Hamzic, D Kummer, TK Froehlich, M Joerger, S Aebi, C Palles, ... Pharmacological research 152, 104594, 2020 | 32 | 2020 |
| Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients … P García-Alfonso, M Saiz-Rodríguez, R Mondéjar, J Salazar, D Páez, ... Clinical and Translational Oncology, 1-12, 2022 | 31 | 2022 |
| Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem? S Osorio, V Escudero-Vilaplana, I Gómez-Centurión, R Pérez-López, ... Annals of Hematology 97, 2089-2098, 2018 | 24 | 2018 |
| Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan S Salvador-Martín, X García-González, MI García, C Blanco, ... Pharmacological research 136, 133-139, 2018 | 24 | 2018 |
| Systematic therapeutic drug monitoring for linezolid: variability and clinical impact A Galar, M Valerio, P Muñoz, L Alcalá, X García-González, A Burillo, ... Antimicrobial Agents and Chemotherapy 61 (10), 10.1128/aac. 00687-17, 2017 | 24 | 2017 |
| Valganciclovir—ganciclovir use and systematic therapeutic drug monitoring. An invitation to antiviral stewardship A Galar, M Valerio, P Catalán, X García-González, A Burillo, ... Antibiotics 10 (1), 77, 2021 | 19 | 2021 |
| Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity M Pellicer, X García-González, MI García, C Blanco, P García-Alfonso, ... Pharmacogenomics 18 (13), 1215-1223, 2017 | 18 | 2017 |
| New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine X García-González, B Kaczmarczyk, J Abarca-Zabalía, F Thomas, ... Cancer Chemotherapy and Pharmacology 86, 45-54, 2020 | 16 | 2020 |
| Genetic predictors of long-term response to antitumor necrosis factor agents in pediatric inflammatory bowel disease S Salvador-Martín, F Bossacoma, G Pujol-Muncunill, VM Navas-López, ... Journal of pediatric gastroenterology and nutrition 71 (4), 508-515, 2020 | 15 | 2020 |
| PCSK9 inhibitors revisited: effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort J Vicente-Valor, X García-González, S Ibáñez-García, ME Durán-García, ... Biomedicine & Pharmacotherapy 146, 112519, 2022 | 14 | 2022 |
| Improving surgical antibiotic prophylaxis adherence and reducing hospital readmissions: a bundle of interventions including health information technologies A Ribed, B Monje, X García-González, M Sanchez-Somolinos, ... European Journal of Hospital Pharmacy 27 (4), 237-242, 2020 | 13 | 2020 |
| Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin S Osorio, V Escudero-Vilaplana, I Gómez-Centurión, E González-Arias, ... Journal of Oncology Pharmacy Practice 25 (3), 694-698, 2019 | 13 | 2019 |
| Finding the dose for ceftolozane-tazobactam in critically ill children with and without acute kidney injury L Butragueño-Laiseca, IF Troconiz, S Grau, N Campillo, X García, ... Antibiotics 9 (12), 887, 2020 | 11 | 2020 |
| Efficiency of biological therapies in patients with moderate to severe psoriasis: impact of a pharmacotherapeutic protocol RM Romero-Jimenez, V Escudero-Vilaplana, O Baniandres Rodriguez, ... Journal of Dermatological Treatment 27 (3), 198-202, 2016 | 10 | 2016 |
| Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome V Escudero‐Vilaplana, X Garcia‐Gonzalez, S Osorio‐Prendes, ... Journal of clinical pharmacy and therapeutics 41 (1), 59-63, 2016 | 9 | 2016 |
